Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide with Prednisone, Cyclophosphamide, Etoposide, and Methotrexate for Relapsed/Refractory PTCL
ChiCTR-IIC-15006786Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in peripheral T-cell lymphoma (PTCL), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective remission rate. Started Jun 2016; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on ChiCTR-IIC-15006786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIC-15006786.